Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
NCT04210843 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2024-06-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to a strategic decision by Novartis to discontinue development of ligelizumab in CSU. This decision was not based on any safety concerns.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-29Also stopped (terminated): Novartis Pharmaceuticals, ligelizumab + Placebo (NCT04984876)
- 2024-10-08Results posted on the registry: Novartis Pharmaceuticals, ligelizumab + Placebo (NCT04984876)
- 2024-09-19Also stopped (terminated): Stanford University, omalizumab + dupliumab (NCT04943744)
- 2024-07-03Also stopped (withdrawn): University of California, Davis, Rituximab combined with Omalizumab (NCT04128176)
- 2024-06-18Also stopped (terminated): Novartis Pharmaceuticals, Ligelizumab (NCT05024058)
- 2024-06-18Also stopped (terminated): Novartis Pharmaceuticals, Ligelizumab + Placebo (NCT04513548)
- 2024-06-04Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Omalizumab + Placebo for Omalizumab (NCT03881696)
- 2024-05-01Results posted on the registry: Amgen, Tezepelumab Dose 1 + Tezepelumab Dose 2 (NCT04833855)
- 2024-04-15Phase 3 first posted: Taizhou Mabtech Pharmaceutical Co.,Ltd, CMAB007 + Xolair (NCT06365879)
- 2024-03-25Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580356)
- 2024-03-08Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab (NCT03907878)
- 2023-12-11Also stopped (terminated): Carsten Bindslev-Jensen, Omalizumab Injection (NCT03964051)
- 2023-09-18Phase 3 first posted: Novartis Pharmaceuticals, Remibrutinib + Placebo to remibrutinib (NCT06042478)
- 2023-09-15Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab (NCT05024058)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision